PDF herunterladen
Thromb Haemost 1999; 81(02): 312-313
DOI: 10.1055/s-0037-1614462
Letters to the Editor
Schattauer GmbH

The Prevalence of Factor V Arg306→Thr (Factor V Cambridge) and Factor V Arg306→Gly Mutations in Different Human Populations

R. F. Franco
1   From the Department of Clinical Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil
,
J. Elion
2   Laboratoire de Biochimie Génétique, INSERM U458, Paris, France
,
M. H. Tavella
1   From the Department of Clinical Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil
,
S. E. B. Santos
3   Federal University of Para, Brazil
,
M. A. Zago
1   From the Department of Clinical Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received14. August 1998

Accepted after revision04. November 1998

Publikationsdatum:
08. Dezember 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

 

 

  • References

  • 1 Dählback B. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol 1997; 34: 217-34.
    PubMedSuche in Google Scholar
  • 2 Bertina RM, Koeleman PC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
    CrossrefPubMedSuche in Google Scholar
  • 3 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-4.
    PubMedSuche in Google Scholar
  • 4 Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135-9.
    PubMedSuche in Google Scholar
  • 5 Rees DC, Cos M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
    CrossrefPubMedSuche in Google Scholar
  • 6 Franco RF, Araújo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677 C→T mutation in the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998; 79: 119-21.
    Thieme ConnectPubMedSuche in Google Scholar
  • 7 Franco RF, Santos SEB, Elion J, Tavella MH, Zago MA. The prevalence of the G20210A polymorphism in the 3’- untranslated region of the prothrombin gene in different human populations. Acta Haematologica 1998; 100: 9-12.
    CrossrefPubMedSuche in Google Scholar
  • 8 Rosendaal F, Doggen C, Zivelin A, Arruda V, Aiach M, Siscovick D, Hillarp A, Watzke H, Bernardi F, Cumming A, Preston F, Reitsma P. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-8.
    Thieme ConnectPubMedSuche in Google Scholar
  • 9 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7.
    CrossrefPubMedSuche in Google Scholar
  • 10 Franco RF, Maffei FH, Lourenço D, Morelli V, Thomazini IA, Piccinato CE, Tavella MH, Zago MA. Factor V Arg306→Thr (factor V Cambridge) and factor V Arg306→Gly mutations in venous thrombotic disease. Br J Haematol 1998; 103: 888-90.
    CrossrefPubMedSuche in Google Scholar